跳至主要内容
临床试验/JPRN-UMIN000005853
JPRN-UMIN000005853招募中未知

Randomized Phase 2 Trial of Inhaled Furosemide on the dyspnea associated with Cancer - Randomized Phase 2 Trial of Inhaled Furosemide on the dyspnea associated with Cancer

Chiba University Hospital0 个研究点目标入组 60 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • I. The first stage 1) Hypersensitivity reactions to furosemide, opioids and sulfonamide derivatives 2) Severe heart failure, respiratory disease with unstable dyspnea 3) Neurological, mental impairment with the difficulty of collecting data 4) Drug abuse, drug dependence 5) Pregnancy, lactation II. The second stage 1) Inability to take oral rapid onset morphine 2) Pain score above 3 3) Severe hypertention(SBP >= 180mmHg or DBP >= 110mmHg) 4) Liver failure, renal failure AST(GOT) >= 100IU/L ALT(GPT) >= 100IU/L T.bil >= 2.0mg/dL eGFR <= 30 mL/hr 5) Severe respiratory failure or the administration of oxygen with flow rate of 10L/min or more 6) Ineligible condition for study in physician's judge 7) The change in prescription of opioid, steroids and anxiolytics within 2 days prior to study 8) The change in the chemotherapy within 7 days prior to study

研究者

相似试验